Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia

Molecular Therapy

Volumn 23, Issue 4, 2015, Pages 648-655

  Durben, Michael ^a,c   Schmiedel, Dominik ^a   Hofmann, Martin ^a,c   Vogt, Fabian ^a,b   Nübling, Tina ^a   Pyz, Elwira ^a   Bühring, Hans Jörg ^a   Rammensee, Hans Georg ^a,b   Salih, Helmut R ^a,b   Große Hovest, Ludger ^a,c   Jung, Gundram ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c SYNIMMUNE GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD3 ANTIBODY; FC RECEPTOR; BISPECIFIC ANTIBODY; CD3 ANTIGEN; FLT3 PROTEIN, MOUSE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ARTICLE; CELL AGGREGATION; CELL KILLING; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROCESS OPTIMIZATION; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; IMMUNOLOGY; LEUKEMIA, EXPERIMENTAL; MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; FMS-LIKE TYROSINE KINASE 3; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 84927006760     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.2     Document Type: Article

References (30)

1. Lazar, GA, Dang, W, Karki, S, Vafa, O, Peng, JS, Hyun, L et al. (2006). Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103: 4005-4010.
2. Desjarlais, JR and Lazar, GA (2011). Modulation of antibody effector function. Exp Cell Res 317: 1278-1285.
3. Horton, HM, Bernett, MJ, Pong, E, Peipp, M, Karki, S, Chu, SY et al. (2008). Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 68: 8049-8057.
4. Foyil, KV and Bartlett, NL (2010). Anti-CD30 Antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 5: 140-147.
5. Horton, HM, Bernett, MJ, Peipp, M, Pong, E, Karki, S, Chu, SY et al. (2010). Fcengineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116: 3004-3012.
6. Hofmann, M, Große-Hovest, L, Nübling, T, Pyz, E, Bamberg, ML, Aulwurm, S et al. (2012). Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia 26: 1228-1237.
7. Staerz, UD, Kanagawa, O and Bevan, MJ (1985). Hybrid antibodies can target sites for attack by T cells. Nature 314: 628-631.
8. Perez, P, Hoffman, RW, Shaw, S, Bluestone, JA and Segal, DM (1985). Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316: 354-356.
9. Jung, G, Ledbetter, JA and Müller-Eberhard, HJ (1987). Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci USA 84: 4611-4615.
10. Canevari, S, Stoter, G, Arienti, F, Bolis, G, Colnaghi, MI, Di Re, EM et al. (1995). Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87: 1463-1469.
11. Nitta, T, Sato, K, Yagita, H, Okumura, K and Ishii, S (1990). Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368-371.
12. Marmé, A, Strauss, G, Bastert, G, Grischke, EM and Moldenhauer, G (2002). Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 101: 183-189.
13. Heiss, MM, Murawa, P, Koralewski, P, Kutarska, E, Kolesnik, OO, Ivanchenko, VV et al. (2010). The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 127: 2209-2221.
14. Jung, G and Eberhard, HJ (1988). An in-vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol Today 9: 257-260.
15. Jung, G, Freimann, U, Von Marschall, Z, Reisfeld, RA and Wilmanns, W (1991). Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 21: 2431-2435.
16. Mack, M, Riethmüller, G and Kufer, P (1995). A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92: 7021-7025.
17. Bargou, R, Leo, E, Zugmaier, G, Klinger, M, Goebeler, M, Knop, S et al. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974-977.
18. Topp, MS, Kufer, P, Gökbuget, N, Goebeler, M, Klinger, M, Neumann, S et al. (2011). Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29: 2493-2498.
19. Kroesen, BJ, Buter, J, Sleijfer, DT, Janssen, RA, van der Graaf, WT, The, TH et al. (1994). Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 70: 652-661.
20. Tibben, JG, Boerman, OC, Massuger, LF, Schijf, CP, Claessens, RA and Corstens, FH (1996). Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int J Cancer 66: 477-483.
21. Klinger, M, Brandl, C, Zugmaier, G, Hijazi, Y, Bargou, RC, Topp, MS et al. (2012). Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119: 6226-6233.
22. Wörn, A and Plückthun, A (2001). Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305: 989-1010.
23. Schoonjans, R, Willems, A, Schoonooghe, S, Fiers, W, Grooten, J and Mertens, N (2000). Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 165: 7050-7057.
24. Rappold, I, Ziegler, BL, Köhler, I, Marchetto, S, Rosnet, O, Birnbaum, D et al. (1997). Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 90: 111-125.
25. Grosse-Hovest, L, Hartlapp, I, Marwan, W, Brem, G, Rammensee, HG and Jung, G (2003). A recombinant bispecific single-chain antibody induces targeted, supraagonistic CD28-stimulation and tumor cell killing. Eur J Immunol 33: 1334-1340.
26. Otz, T, Grosse-Hovest, L, Hofmann, M, Rammensee, HG and Jung, G (2009). A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 23: 71-77.
27. Aigner, M, Feulner, J, Schaffer, S, Kischel, R, Kufer, P, Schneider, K et al. (2013). T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27: 1107-1115.
28. Arndt, C, von Bonin, M, Cartellieri, M, Feldmann, A, Koristka, S, Michalk, I et al. (2013). Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 27: 964-967.
29. Ginaldi, L, De Martinis, M, Matutes, E, Farahat, N, Morilla, R and Catovsky, D (1998). Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51: 364-369.
30. Shearman, CW, Pollock, D, White, G, Hehir, K, Moore, GP, Kanzy, EJ et al. (1991). Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor. J Immunol 147: 4366-4373.